Solutions for clinical-grade manufacturing of gene-engineered NK cells
On demand

Solutions for clinical-grade manufacturing of gene-engineered NK cells

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Solutions for clinical-grade manufacturing of gene-engineered NK cells

Due to their central role in tumor immunosurveillance and unique ability to recognize target cells in a non-MHC-restricted manner, natural killer (NK) cells represent a promising immunotherapy for cancer treatment, in particular as an off-the-shelf approach.

Inspired by the success of CAR T cell therapies, researchers are incorporating the genetic engineering of NK cells as a strategy in the latest pre-clinical and clinical studies to empower NK cells and enhance their anti-tumor effector functions.

As clinical trials progress, there is an increased need to establish standardized manufacturing methods for gene-engineered NK cells for cancer therapy.

However, it is challenging to genetically modify and ex vivo-expand NK cells — and these two steps are crucial for the sufficient generation of functional engineered NK cells.

In this webinar, Miltenyi's Maria Delso Vallejo, PhD will address how to efficiently manufacture gene-engineered NK cells for clinical applications using an automated and closed system.

Furthermore, Maria will explore options to upscale NK cell manufacturing and standardize the in-process control (IPC) and quality control (QC) steps associated with the process.

  • Discover solutions to standardize the clinical manufacturing of your gene-engineered NK cells using an automated and closed system
  • Learn how you can achieve robust ex vivo expansion of your NK cells and explore options for upscaling
  • Understand how to leverage automated flow cytometric analysis for your IPC/QC
Maria Delso Vallejo
Maria Delso Vallejo
Global Product Manager, Immunotherapy at Miltenyi Biotec

María Delso Vallejo is responsible for the clinical NK cell applications portfolio at Miltenyi Biotec. She received her PhD in biology at Hannover Medical School, Germany in 2018. While studying for her doctorate, Maria worked as a Marie Curie Early Stage Researcher, studying the ex vivo expansion of NK cells for their use in immunotherapy against cancer. After joining the Miltenyi Biotec Global Marketing team in 2017, she spent 5 years as Product Manager for the sample preparation reagent portfolio. Since 2022, Maria has taken care of the clinical NK cell portfolio working closely with R&D to advance the development of tools to enable NK cell therapy manufacturing.